Inmune Bio CEO Resigns, New Leadership Appointed
Ticker: INMB · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, management-transition, ceo-appointment
TL;DR
Glickman OUT as CEO of Inmune Bio, Buller IN. Big changes coming.
AI Summary
On March 26, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of David M. Glickman from his role as Chief Executive Officer and a member of the Board of Directors. The company also announced the appointment of Gregory T. Buller as the new CEO and Chairman of the Board, effective immediately. This transition is part of the company's strategic realignment to advance its drug development programs.
Why It Matters
This leadership change could signal a shift in the company's strategic direction and operational focus, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, introduce uncertainty regarding future strategy and execution, which can be a medium-term risk.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- David M. Glickman (person) — Resigning CEO and Board Member
- Gregory T. Buller (person) — Appointed CEO and Chairman of the Board
- March 26, 2024 (date) — Date of earliest event reported
FAQ
What was the effective date of David M. Glickman's resignation?
The filing does not explicitly state the effective date of David M. Glickman's resignation, but it was reported on March 26, 2024.
Who has been appointed as the new CEO of Inmune Bio?
Gregory T. Buller has been appointed as the new CEO of Inmune Bio.
What other role will Gregory T. Buller assume?
Gregory T. Buller will also serve as the Chairman of the Board.
What is the stated reason for this leadership transition?
The transition is part of the company's strategic realignment to advance its drug development programs.
In which state is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2024-03-27 16:07:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0202742-8k_inmune.htm (8-K) — 23KB
- ea020274201ex99-1_inmune.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-026597.txt ( ) — 213KB
- inmb-20240326.xsd (EX-101.SCH) — 3KB
- inmb-20240326_lab.xml (EX-101.LAB) — 33KB
- inmb-20240326_pre.xml (EX-101.PRE) — 22KB
- ea0202742-8k_inmune_htm.xml (XML) — 4KB
01. Other
Item 8.01. Other Events. On March 26, 2024, INmune Bio Inc. issued a press release announcing it will host a conference call on Thursday, March 28, 2024 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2023 and to provide a corporate update. A copy of the press release is attached herewith as Exhibit 99.1.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated March 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: March 27, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2